Mr. Pankaj R. Patel
Mr. Pankaj R. Patel is the Chairman and Managing Director of Zydus Cadila - Cadila Healthcare Ltd. Zydus Cadila is an innovative,global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies in over 50 countries worldwide.
With a core competence in the field of healthcare, Zydus provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. The group has 1200 researchers across 19 sites converging to look at differentiated medicines for the future. From APIs to vaccines, biosimilars and niche technologies, the company looks at different ideas and concepts to bridge unmet healthcare needs.
Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis was launched in December 2014 by Zydus.
Zydus is also the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world's first drug to be approved for the treatment of diabetic dyslipidemia.
Mr. Pankaj Patel is currently the President of the Federation of Indian Chamber of Commerce & Industry (FICCI). He is a Member of the Board of Governers of the Indian Institute of Management (IIM), Ahmedabad. He is also the Chairman of the Board of Governers and Society, IIM, Udaipur. He is the Chairperson of the Board of Governors of IIT, Bhubaneswar. Mr. Patel is currently on the Governing Board of The Ahmedabad University and the Chairman of School of Life Sciences, Ahmedabad University. He is also a Member of the Board of Management of the Narsee Monjee Institute of Management Studies and a Member on the Governing Board of the Gujarat Law Society and Nirma University.
He is the Executive Chairman, Vice President and Trustee of the Gujarat Cancer Society and Chairman of the Gujarat Cancer and Research Institute, a Regional Cancer Centre and one of the largest cancer centres of India, reaching out to the needy and underprivileged cancer patients.